SanBio Company Limited

SanBio Company Limited

SNBIF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$393.41M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
SanBio Company LimitedSanBio Company Limited-17.6--31%-0.1
$1.19

Current Fair Value

76.5% downside

Overvalued by 76.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$393.41 Million
Enterprise Value$-11,228,292,680.00
Earnings per Share$-52.63
Beta0.28
Outstanding Shares78,058,000

Return

Return on Equity-31.00%ROE
Return on Assets-26.64%
Return on Invested Capital-27.79%

Valuation & Multiples

P/E Ratio-17.65P/E Ratio
PEG-16.79PEG
Price to Sales-Price to Sales
Price to Book Ratio0.03Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-14.63
Enterprise Value to Net Income3
Total Debt to Enterprise0.02
Debt to Equity0.1Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 14, 2026
EPS
-$0.08
Est. -$0.03
Revenue Estimate
$1.87 M
Consensus analyst estimate

Next Earnings Call

Expected Date
December 15, 2026
EPS Estimate
-$0.05
Consensus analyst estimate
Revenue Estimate
$100.00 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About SanBio Company Limited

33 employees
CEO: Keita Mori

SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment tha...